Fulgent Cash And Cash Equivalents Changes from 2010 to 2025
| FLGT Stock | USD 16.57 0.27 1.60% |
Cash And Cash Equivalents Changes | First Reported 2017-03-31 | Previous Quarter -13.4 M | Current Value -7.6 M | Quarterly Volatility 68.4 M |
Check Fulgent Genetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fulgent Genetics' main balance sheet or income statement drivers, such as Discontinued Operations of 49.5 K, Depreciation And Amortization of 31.6 M or Interest Expense of 44.7 M, as well as many indicators such as Price To Sales Ratio of 3.25, Dividend Yield of 0.018 or PTB Ratio of 0.83. Fulgent financial statements analysis is a perfect complement when working with Fulgent Genetics Valuation or Volatility modules.
Fulgent | Cash And Cash Equivalents Changes |
Latest Fulgent Genetics' Cash And Cash Equivalents Changes Growth Pattern
Below is the plot of the Cash And Cash Equivalents Changes of Fulgent Genetics over the last few years. It is Fulgent Genetics' Cash And Cash Equivalents Changes historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fulgent Genetics' overall financial position and show how it may be relating to other accounts over time.
| Cash And Cash Equivalents Changes | 10 Years Trend |
|
Cash And Cash Equivalents Changes |
| Timeline |
Fulgent Cash And Cash Equivalents Changes Regression Statistics
| Arithmetic Mean | 34,135,728 | |
| Coefficient Of Variation | 112.50 | |
| Mean Deviation | 35,684,911 | |
| Median | 7,399,000 | |
| Standard Deviation | 38,401,832 | |
| Sample Variance | 1474.7T | |
| Range | 94.9M | |
| R-Value | 0.83 | |
| Mean Square Error | 478.7T | |
| R-Squared | 0.70 | |
| Significance | 0.000057 | |
| Slope | 6,734,322 | |
| Total Sum of Squares | 22120.5T |
Fulgent Cash And Cash Equivalents Changes History
About Fulgent Genetics Financial Statements
Fulgent Genetics shareholders use historical fundamental indicators, such as Cash And Cash Equivalents Changes, to determine how well the company is positioned to perform in the future. Although Fulgent Genetics investors may analyze each financial statement separately, they are all interrelated. The changes in Fulgent Genetics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Fulgent Genetics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash And Cash Equivalents Changes | 89 M | 93.5 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.